No price history available.
Key financial summary
Financials in SEK| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | SEKm | 240 | 770 | 1,829 | 2,338 | 2,540 | 2,695 | N/A | N/A |
| Operating profit | SEKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | SEKm | 49 | 55 | 95 | 59 | 99 | 56 | N/A | N/A |
| EPS reported | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | SEKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | SEKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | SEKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in SEK| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Swedencare AB (publ), an enterprise established in 1993 and headquartered in Malmö, Sweden, operates with its subsidiaries to develop, produce, market, and sell a wide array of healthcare products, predominantly for animals. The company's flagship offering is the ProDen PlaqueOff line, focused on dental hygiene for dogs and cats. This popular range includes a food supplement powder designed to reduce plaque and tartar buildup, along with various chewable formats such as dental bites, bones (including mini versions for smaller dogs), and soft chews suitable for both felines and canines. Beyond dental care, Swedencare provides an extensive selection of nutritional supplements under the NutriScience brand for cats, dogs, and horses. These products address diverse health requirements: Glucosamine and Stomax aid in the rejuvenation of joint cartilage, bones, muscles, ligaments, and sinews; ArthriAid supports joint function and mobility; KalmAid offers a calming effect for anxious dogs; while OmegaAid and RevitalAid are formulated to promote healthy skin and coats. Furthermore, the company manufactures specialized supplements for horses, including Gastrocare to alleviate gastric pain and enhance appetite; Equine Gold for overall vitality; a horse-specific ArthriAid to assist with cartilage formation; and AnxiKalm, aimed at soothing excitable horses. Interestingly, Swedencare also caters to human health with ProDen PlaqueOff Teeth and Gums, a natural dietary supplement designed to boost oral hygiene and prevent tartar accumulation. The company's products are distributed through a broad network that includes pharmacies, veterinary clinics, pet stores, animal hospitals, and online channels.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Swedencare AB (publ) (SECARE.ST)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Swedencare AB (publ), an enterprise established in 1993 and headquartered in Malmö, Sweden, operates with its subsidiaries to develop, produce, market, and sell a wide array of healthcare products, predominantly for animals. The company's flagship offering is the ProDen PlaqueOff line, focused on dental hygiene for dogs and cats. This popular range includes a food supplement powder designed to reduce plaque and tartar buildup, along with various chewable formats such as dental bites, bones (including mini versions for smaller dogs), and soft chews suitable for both felines and canines. Beyond dental care, Swedencare provides an extensive selection of nutritional supplements under the NutriScience brand for cats, dogs, and horses. These products address diverse health requirements: Glucosamine and Stomax aid in the rejuvenation of joint cartilage, bones, muscles, ligaments, and sinews; ArthriAid supports joint function and mobility; KalmAid offers a calming effect for anxious dogs; while OmegaAid and RevitalAid are formulated to promote healthy skin and coats. Furthermore, the company manufactures specialized supplements for horses, including Gastrocare to alleviate gastric pain and enhance appetite; Equine Gold for overall vitality; a horse-specific ArthriAid to assist with cartilage formation; and AnxiKalm, aimed at soothing excitable horses. Interestingly, Swedencare also caters to human health with ProDen PlaqueOff Teeth and Gums, a natural dietary supplement designed to boost oral hygiene and prevent tartar accumulation. The company's products are distributed through a broad network that includes pharmacies, veterinary clinics, pet stores, animal hospitals, and online channels.